www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Infectious diseases
All latest versions
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Bacterial infections
Bezlotoxumab
Ceftobiprole
Citric acid / lactic acid / potassium bitartrate
IND
Clindamycin
Dalbavancine
IND
Durlobactam / sulbactam
Eravacycline
Gepotidacin
Oritavancin diphosphate
IND
Ridinilazole
SER 109
Tebipenem
COVID-19
Baricitinib
IND
Casirivimab / imdevimab
Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg .
Extension of indication to include treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result.
IND
Molnupiravir
PF-07321332 / ritonavir
Remdesivir
Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment
IND
Treatment of paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
IND
Tixagevimab / cilgavimab
Pre-expositie profylaxe van COVID-19 bij volwassenen en adolescenten van 12 jaar en ouder met een lichaamsgewicht van tenminste 40 kilo
Evusheld is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40kg) with COVID‑19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
IND
Fungal infections
Oteseconazole
Rezafungin
HIV
Raltegravir
BS
Semzuvolimab
Infectious diseases other
Baloxavir marboxil
IND
Cefepime / Enmetazobactam
Cefepime/taniborbactam
Fluticasone propionate
Parasitic infections
Lotilaner
Viral infections other
Bizalimogene ralaplasmid
Bulevirtide
Letermovir
Extension of indication to include treatment of prophylaxis of cytomegalovirus in kidney transplant recipients (KTR) for PREVYMIS.
IND
Extension of Letermovir From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant
IND
Lonafarnib
IND
Maribavir
Nirsevimab
Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.
Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season
IND
Posoleucel
Tenofovir alafenamide
IND
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
About the Horizon Scan
Nederlands
English